Vectura announced on Thursday, August 12, that it plans to back tobacco giant Philip Morris International’s £1.1 billion (US$1.52 billion) offer for the British drugmaker, days after private equity firm Carlyle decided against raising its bid.
Related: Philip Morris Ups Bid For UK’s Vectura
On Sunday, Philip Morris sweetened its offer for Vectura, which makes inhaled treatments, to 165 pence per share, surpassing Carlyle’s final 155 pence proposal.
Vectura stated it considered the terms of the Philip Morris offer to be fair and reasonable, and its board plans to unanimously recommend the bid to shareholders.
Carlyle offered to buy Vectura for about £958 million (US$1.3 billion). Vectura, which makes respiratory treatments, had stated on Friday that it was backing Carlyle’s offer and withdrawing its recommendation for Philip Morris’ proposal, adding that it might be better positioned under Carlyle’s ownership.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Spanish Startup Association Slams Microsoft’s Cloud Practices
May 7, 2024 by
CPI
TikTok and ByteDance File Lawsuit Against US Law Mandating App Sale
May 7, 2024 by
CPI
Apollo, Sony Bid to Acquire Paramount Faces Regulatory Hurdles
May 7, 2024 by
CPI
Turkey Fines Meta $10.4 Million for Abusing Market Dominance
May 6, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI